419 related articles for article (PubMed ID: 29515589)
1. Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection.
Baldwin SL; Hsu FC; Van Hoeven N; Gage E; Granger B; Guderian JA; Larsen SE; Lorenzo EC; Haynes L; Reed SG; Coler RN
Front Immunol; 2018; 9():295. PubMed ID: 29515589
[TBL] [Abstract][Full Text] [Related]
2. DAMP-Inducing Adjuvant and PAMP Adjuvants Parallelly Enhance Protective Type-2 and Type-1 Immune Responses to Influenza Split Vaccination.
Hayashi T; Momota M; Kuroda E; Kusakabe T; Kobari S; Makisaka K; Ohno Y; Suzuki Y; Nakagawa F; Lee MSJ; Coban C; Onodera R; Higashi T; Motoyama K; Ishii KJ; Arima H
Front Immunol; 2018; 9():2619. PubMed ID: 30515151
[TBL] [Abstract][Full Text] [Related]
3. Overcoming the Neonatal Limitations of Inducing Germinal Centers through Liposome-Based Adjuvants Including C-Type Lectin Agonists Trehalose Dibehenate or Curdlan.
Vono M; Eberhardt CS; Mohr E; Auderset F; Christensen D; Schmolke M; Coler R; Meinke A; Andersen P; Lambert PH; Mastelic-Gavillet B; Siegrist CA
Front Immunol; 2018; 9():381. PubMed ID: 29541075
[TBL] [Abstract][Full Text] [Related]
4. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
Goff PH; Hayashi T; MartÃnez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
[TBL] [Abstract][Full Text] [Related]
5. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
[TBL] [Abstract][Full Text] [Related]
6. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
[TBL] [Abstract][Full Text] [Related]
7. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion.
Baldwin SL; Shaverdian N; Goto Y; Duthie MS; Raman VS; Evers T; Mompoint F; Vedvick TS; Bertholet S; Coler RN; Reed SG
Vaccine; 2009 Oct; 27(43):5956-63. PubMed ID: 19679214
[TBL] [Abstract][Full Text] [Related]
8. A De-
Ryu JI; Park SA; Wui SR; Ko A; Han JE; Choi JA; Song MK; Kim KS; Cho YJ; Lee NG
Biomed Res Int; 2016; 2016():3713656. PubMed ID: 27891512
[TBL] [Abstract][Full Text] [Related]
9. Use of the Microparticle Nanoscale Silicon Dioxide as an Adjuvant To Boost Vaccine Immune Responses against Influenza Virus in Neonatal Mice.
Russell RF; McDonald JU; Lambert L; Tregoning JS
J Virol; 2016 May; 90(9):4735-4744. PubMed ID: 26912628
[TBL] [Abstract][Full Text] [Related]
10. Novel Lipidated Imidazoquinoline TLR7/8 Adjuvants Elicit Influenza-Specific Th1 Immune Responses and Protect Against Heterologous H3N2 Influenza Challenge in Mice.
Miller SM; Cybulski V; Whitacre M; Bess LS; Livesay MT; Walsh L; Burkhart D; Bazin HG; Evans JT
Front Immunol; 2020; 11():406. PubMed ID: 32210973
[TBL] [Abstract][Full Text] [Related]
11. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
Lei H; Peng X; Jiao H; Zhao D; Ouyang J
Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
[TBL] [Abstract][Full Text] [Related]
12. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.
van de Sandt CE; Kreijtz JH; Geelhoed-Mieras MM; Vogelzang-van Trierum SE; Nieuwkoop NJ; van de Vijver DA; Fouchier RA; Osterhaus AD; Morein B; Rimmelzwaan GF
Vaccine; 2014 Sep; 32(43):5614-23. PubMed ID: 25140929
[TBL] [Abstract][Full Text] [Related]
13. IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants.
Desbien AL; Dubois Cauwelaert N; Reed SJ; Bailor HR; Liang H; Carter D; Duthie MS; Fox CB; Reed SG; Orr MT
J Immunol; 2016 Dec; 197(11):4351-4359. PubMed ID: 27794001
[TBL] [Abstract][Full Text] [Related]
14. A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity.
Sato-Kaneko F; Yao S; Lao FS; Shpigelman J; Messer K; Pu M; Shukla NM; Cottam HB; Chan M; Chu PJ; Burkhart D; Schoener R; Matsutani T; Carson DA; Corr M; Hayashi T
Front Immunol; 2020; 11():1207. PubMed ID: 32636840
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
[TBL] [Abstract][Full Text] [Related]
16. Identification of GLA/SE as an effective adjuvant for the induction of robust humoral and cell-mediated immune responses to EBV-gp350 in mice and rabbits.
Heeke DS; Lin R; Rao E; Woo JC; McCarthy MP; Marshall JD
Vaccine; 2016 May; 34(23):2562-9. PubMed ID: 27085175
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
[TBL] [Abstract][Full Text] [Related]
18. GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza.
Clegg CH; Roque R; Perrone LA; Rininger JA; Bowen R; Reed SG
PLoS One; 2014; 9(2):e88979. PubMed ID: 24551202
[TBL] [Abstract][Full Text] [Related]
19. [Increasing the immunogenicity of inactivated chitosan adjuvanted vaccine from A/California/7/09 (H1N1) strain and analyzing the antigenic specificity of this influenza virus strain].
Gendon IuZ; Markushin SG; Vasil'ev IuM; Akopova II; Krivtsov GG
Vopr Virusol; 2012; 57(1):28-33. PubMed ID: 22624470
[TBL] [Abstract][Full Text] [Related]
20. Archaeal glycolipid adjuvanted vaccines induce strong influenza-specific immune responses through direct immunization in young and aged mice or through passive maternal immunization.
Stark FC; Akache B; Ponce A; Dudani R; Deschatelets L; Jia Y; Sauvageau J; Williams D; Jamshidi MP; Agbayani G; Wachholz K; Harrison BA; Li X; Krishnan L; Chen W; McCluskie MJ
Vaccine; 2019 Nov; 37(47):7108-7116. PubMed ID: 31383490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
